GlycoMimetics Non Operating Income Net Other vs Ebitda Analysis
| GLYC Stock | USD 0.32 0.03 10.34% |
GlycoMimetics financial indicator trend analysis is much more than just examining GlycoMimetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlycoMimetics is a good investment. Please check the relationship between GlycoMimetics Non Operating Income Net Other and its Ebitda accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.
Non Operating Income Net Other vs Ebitda
Non Operating Income Net Other vs Ebitda Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlycoMimetics Non Operating Income Net Other account and Ebitda. At this time, the significance of the direction appears to have pay attention.
The correlation between GlycoMimetics' Non Operating Income Net Other and Ebitda is -0.88. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Ebitda in the same time period over historical financial statements of GlycoMimetics, assuming nothing else is changed. The correlation between historical values of GlycoMimetics' Non Operating Income Net Other and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of GlycoMimetics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Non Operating Income Net Other i.e., GlycoMimetics' Non Operating Income Net Other and Ebitda go up and down completely randomly.
Correlation Coefficient | -0.88 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Non Operating Income Net Other
Ebitda
Most indicators from GlycoMimetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlycoMimetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 2,017, whereas Selling General Administrative is forecasted to decline to about 13.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 264.6K | 207.1K | 175.7K | 198.4K | Interest Income | 19.8K | 714.5K | 2.2M | 1.3M |
GlycoMimetics fundamental ratios Correlations
Click cells to compare fundamentals
GlycoMimetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GlycoMimetics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 168.0M | 142.8M | 94.3M | 51.8M | 45.3M | 88.5M | |
| Other Current Liab | 8.7M | 9.4M | 8.7M | 7.0M | 5.2M | 6.0M | |
| Total Current Liabilities | 11.0M | 12.4M | 11.8M | 8.9M | 6.8M | 9.5M | |
| Total Stockholder Equity | 154.2M | 128.2M | 81.6M | 42.9M | 38.4M | 36.5M | |
| Property Plant And Equipment Net | 3.8M | 2.9M | 1.9M | 993.6K | 767.8K | 1.3M | |
| Net Debt | (154.6M) | (134.2M) | (88.3M) | (47.0M) | (41.0M) | (43.0M) | |
| Retained Earnings | (258.4M) | (309.5M) | (372.9M) | (419.6M) | (456.5M) | (433.7M) | |
| Accounts Payable | 1.4M | 2.1M | 2.1M | 970.2K | 868.1K | 1.5M | |
| Cash | 158.2M | 137.0M | 90.3M | 47.9M | 41.8M | 39.7M | |
| Non Current Assets Total | 5.4M | 4.6M | 4.1M | 1.1M | 1.5M | 2.2M | |
| Other Assets | 321.0 | (169.0) | 1.6M | 411.0 | 1.0 | 0.95 | |
| Cash And Short Term Investments | 158.2M | 137.0M | 90.3M | 47.9M | 41.8M | 39.7M | |
| Common Stock Total Equity | 34.4K | 43.2K | 43.5K | 49.0K | 56.4K | 59.2K | |
| Common Stock Shares Outstanding | 43.3M | 45.7M | 51.5M | 52.5M | 63.3M | 32.9M | |
| Liabilities And Stockholders Equity | 168.0M | 142.8M | 94.3M | 51.8M | 45.3M | 88.5M | |
| Non Current Liabilities Total | 2.8M | 2.2M | 918.6K | 1.9M | 66.8K | 63.5K | |
| Other Current Assets | 4.3B | 1.2M | 532.5K | 2.7M | 1.8M | 1.7M | |
| Other Stockholder Equity | 412.6M | 437.6M | 454.4M | 462.5M | 494.8M | 300.5M | |
| Total Liab | 13.8M | 14.6M | 12.7M | 8.9M | 6.9M | 10.6M | |
| Property Plant And Equipment Gross | 3.8M | 2.9M | 4.3M | 3.4M | 767.8K | 729.4K | |
| Total Current Assets | 162.5M | 138.3M | 90.3M | 50.7M | 43.8M | 86.3M | |
| Common Stock | 43.5K | 49.0K | 52.3K | 54.4K | 64.4K | 35.1K | |
| Property Plant Equipment | 822.9K | 620.7K | 1.9M | 993.6K | 1.1M | 876.5K | |
| Net Tangible Assets | 154.2M | 128.2M | 81.6M | 42.9M | 49.4M | 46.9M | |
| Net Receivables | 186.0K | 2.1K | 1.3K | 144.0K | 175.8K | 148.9K | |
| Retained Earnings Total Equity | (152.3M) | (200.6M) | (258.4M) | (309.5M) | (278.5M) | (264.6M) | |
| Capital Surpluse | 271.9M | 406.0M | 412.6M | 437.6M | 503.3M | 304.1M | |
| Inventory | (4.3B) | (1.2B) | (533.8M) | (144.4K) | (130.0K) | (136.5K) | |
| Net Invested Capital | 154.2M | 128.2M | 81.6M | 42.9M | 38.4M | 36.5M | |
| Net Working Capital | 151.6M | 125.8M | 79.0M | 41.8M | 37.0M | 35.1M | |
| Capital Stock | 43.5K | 49.0K | 52.3K | 54.4K | 64.4K | 56.2K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Quarterly Revenue Growth (1.00) | Return On Assets (0.59) | Return On Equity (1.04) |
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.